(SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone

NCT ID: NCT03388060

Last Updated: 2018-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-01

Study Completion Date

2018-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

compare the efficacy of of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm renal stones.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Urolithiasis is a common morbidity worldwide, affecting 10% to 15% of the population in Europe and North America. A higher prevalence of stone disease is found in hot or dry areas, including 20% to 25% in the Middle East. Radiolucent stones are mostly uric acid (UA) calculi, which varies geographically with worldwide incidence ranges from 5 to 40% and about 7- 10 percent of all calculi. Other rare radiolucent stones include xanthine and 2,8-dihydroxyadenine calculi.

The main etiologic factors for the development of uric acid nephrolithiasis are low urinary pH, hyperuricosuria, and low urinary volume. Practically, all of those who form uric acid stones have persistently low urinary pH, and most excrete normal amounts of uric acid. This suggests the potential importance of urinary pH manipulation in dissolving UA stones. Dissolution therapy for UA calculi is based on hydration and raising the urinary pH. European guidelines recommended that urine pH should be increased to a level above 6. The early published papers discussed the efficacy of oral chemo-dissolution therapy reporting high success rates. Since that era, there have been only a few publications, with widely variable results (15-80% complete dissolution rate).

Retrograde intrarenal surgery (RIRS), shockwave lithotripsy (SWL), and percutaneous nephrolithotomy (PCNL) are the three main non-medical modalities for treating medium-sized renal stones. Resorlu et al., retrospectively compare the outcomes of SWL, PNL, and RSIS for 10-20 mm radiolucent renal calculi of 437 patients and concluded that success rates "defined as stone-free status or asymptomatic insignificant residual fragments \<3 mm." were 66.5, 91.4, and 87 % for SWL, PNL, and RIRS (p\<0.001). in a prospective randomized of 135 patient with 1 to 2 cm radiolucent lower calyceal renal calculi, the 3-month stone-free rate of SWL, RIRS and miniperc was 73.8%, 86.1% and 95.1%, respectively (p =0.01).

Comparing the medical in the form of dissolution therapy versus non-medical in the form of SWL, Elderwy et al, in a prospective study on 87 children with radiolucent renal calculi with length less than 25 mm and a normal upper urinary tract or grade I HN, found that stone-free rate was 72.9% for dissolution therapy vs 82.1% after a single session of shock wave lithotripsy (p = 0.314).

Dissolution success is related to stone size as well as compliance. Larger stones demand longer therapy, and in these cases SWL may increase treatment efficacy by increasing stone surface area. So when Mokhless et al., use combined extracorporeal shock wave lithotripsy and dissolution therapy in radiolucent stone 12-65 mm in the largest diameter, stone-free rate of 100% was achieved in all 24 children after 3 months.9 To the best of our knowledge, there is no controlled trial comparing the efficacy of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm single renal stone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urologic Diseases Stone, Urinary Stone, Kidney ESWL Radiolucent Calculus of Urinary Tract Dissolution

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultrasound guided SWL

ultrasound guided SWL for Radiolucent stone

Group Type ACTIVE_COMPARATOR

Ultrasound guided SWL

Intervention Type PROCEDURE

Ultrasound guided SWL for radiolucent renal stone

Dissolution therapy

Dissolution therapy for Radiolucent stone

Group Type ACTIVE_COMPARATOR

Dissolution therapy

Intervention Type PROCEDURE

Alkalinization dissolution therapy for radiolucent renal stone

Combined ultrasound guided SWL and dissolution therapy

Combined treatment for Radiolucent stone.

Group Type ACTIVE_COMPARATOR

Combined ultrasound guided SWL and dissolution therapy

Intervention Type PROCEDURE

Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound guided SWL

Ultrasound guided SWL for radiolucent renal stone

Intervention Type PROCEDURE

Dissolution therapy

Alkalinization dissolution therapy for radiolucent renal stone

Intervention Type PROCEDURE

Combined ultrasound guided SWL and dissolution therapy

Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient with 1-2.5 cm renal stones.
* Normal Serum creatinine
* Radiolucent stone by X-ray

Exclusion Criteria

* Pregnancy.
* Bleeding diatheses.
* Patients with a pacemaker.
* Uncontrolled UTIs.
* Severe skeletal malformations.
* Severe obesity which prevent targeting of the stone; BMI (40 or more).
* Arterial aneurysm in the vicinity of the stone.
* Anatomical obstruction distal to the stone.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Abdelbaset

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khalid Sheir, MD

Role: STUDY_CHAIR

Shock wave unit chief - Urology and nephrology center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urology and Nephrology Center

Al Mansurah, Aldakahlia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RL STONE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Energy Ramping Versus Fixed Dose ESWL
NCT07334236 NOT_YET_RECRUITING NA